Aseptic meningitis following therapy with immune globulins: a combination of product features and patient characteristics?

about

Aseptic meningitis following therapy with immune globulins: a combination of product features and patient characteristics?

Item

http://www.wikidata.org/entity/Q39221850

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Aseptic meningitis following t ...... s and patient characteristics?

@en

Aseptic meningitis following t ...... s and patient characteristics?

@nl

type

Item

label

Aseptic meningitis following t ...... s and patient characteristics?

@en

Aseptic meningitis following t ...... s and patient characteristics?

@nl

prefLabel

Aseptic meningitis following t ...... s and patient characteristics?

@en

Aseptic meningitis following t ...... s and patient characteristics?

@nl

P1476

Aseptic meningitis following t ...... s and patient characteristics?

@en

P2093

Elisabeth Fuellenhals

http://www.w3.org/2001/XMLSchema#string

Roger Berg

http://www.w3.org/2001/XMLSchema#string

P2860

The challenge of drug-induced aseptic meningitis

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.

Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.

Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis.

Adverse effects of intravenous immunoglobulin therapy.

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease

Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis.

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.

P304

3021-3028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TRF.13886

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27807853

http://www.w3.org/2001/XMLSchema#string

P921

meningitis